These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1099047)

  • 1. Contingent naloxone (N-allylnoroxymorphone) treatment of the paroled narcotic addict.
    Kurland AA; McCabe L; Hanlon TE
    Int Pharmacopsychiatry; 1975; 10(3):157-68. PubMed ID: 1099047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contingent naloxone treatment of the narcotic addict: a pilot study.
    Kurland AA; McCabe L; Hanlon T
    Int J Addict; 1976; 11(1):131-42. PubMed ID: 1254364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled comparison of cyclazocine and naloxone treatment of the paroled narcotic addict.
    Hanlon TE; McCabe OL; Savage C; Kurland AA
    Int Pharmacopsychiatry; 1975; 10(4):240-50. PubMed ID: 765293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
    Arch Gen Psychiatry; 1978 Mar; 35(3):335-40. PubMed ID: 365122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narcotic antagonist treatment of addict parolees--the failure of an effective approach.
    Hanlon TE; McCabe OL; Savage C; Kurland AA
    Compr Psychiatry; 1977; 18(3):211-9. PubMed ID: 858238
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
    Kurland AA; McCabe OL; Hanlon TE; Sullivan D
    Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narcotic antagonist treatment: clinical experience with naltrexone.
    Lewis DC; Mayer J; Hersch RG; Black R
    Int J Addict; 1978 Aug; 13(6):961-73. PubMed ID: 730406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot scheme shows that giving naloxone to families of drug users would save lives.
    Hurley R
    BMJ; 2011 Aug; 343():d5445. PubMed ID: 21868460
    [No Abstract]   [Full Text] [Related]  

  • 9. Naloxone in the treatment of the young heroin abuser.
    Pierson PS; Rapkin RM; Kleber HD
    Am J Drug Alcohol Abuse; 1974; 1(2):243-52. PubMed ID: 4467727
    [No Abstract]   [Full Text] [Related]  

  • 10. The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the prehospital setting.
    Cantwell K; Dietze P; Flander L
    Resuscitation; 2005 Jun; 65(3):315-9. PubMed ID: 15919568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The combined use of scopolamine, naltrexone and naloxone as a rapid, safe and effective detoxification treatment for heroin addicts].
    Yang G; Zhou W; Xu K
    Zhonghua Yi Xue Za Zhi; 1999 Sep; 79(9):679-82. PubMed ID: 11715458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial.
    Dunlop AJ; Brown AL; Oldmeadow C; Harris A; Gill A; Sadler C; Ribbons K; Attia J; Barker D; Ghijben P; Hinman J; Jackson M; Bell J; Lintzeris N
    Drug Alcohol Depend; 2017 May; 174():181-191. PubMed ID: 28371689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methadone-naloxone in combination for the treatment of heroin addicts.
    Parwatikar SD; Knowles RR
    Clin Pharmacol Ther; 1973; 14(6):941-8. PubMed ID: 4584151
    [No Abstract]   [Full Text] [Related]  

  • 14. No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone.
    Jones JD; Campbell A; Metz VE; Comer SD
    Addict Behav; 2017 Aug; 71():104-106. PubMed ID: 28325710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A possibility of the use of low naloxone dosages in the treatment of heroin dependence].
    Nadezhdin AV; Litvinova SV; Tetenova EIu; Mikhalev IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(1):56-7. PubMed ID: 16457136
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of cyclazocine in treating narcotic addicts in a low-intervention setting.
    Kleber H; Kinsella JK; Riordan C; Greaves S; Sweeney D
    Arch Gen Psychiatry; 1974 Jan; 30(1):37-42. PubMed ID: 4808735
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong.
    Newman RG; Whitehill WB
    Lancet; 1979 Sep; 2(8141):485-8. PubMed ID: 90214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A behavioral paradigm for the evaluation of narcotic antagonists.
    Meyer RE; Mirin SM; Altman JL; McNamee HB
    Arch Gen Psychiatry; 1976 Mar; 33(3):371-7. PubMed ID: 944026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone-methadone combination for the treatment of opiate dependence.
    Parwatikar S; Knowles RR
    Proc Natl Conf Methadone Treat; 1973; 2():1350-4. PubMed ID: 4612373
    [No Abstract]   [Full Text] [Related]  

  • 20. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.